Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 01-07-2020 | Computed Tomography | Guidelines

EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0

Authors: Silvia Morbelli, Giuseppe Esposito, Javier Arbizu, Henryk Barthel, Ronald Boellaard, Nico I. Bohnen, David J Brooks, Jacques Darcourt, John C. Dickson, David Douglas, Alexander Drzezga, Jacob Dubroff, Ozgul Ekmekcioglu, Valentina Garibotto, Peter Herscovitch, Phillip Kuo, Adriaan Lammertsma, Sabina Pappata, Iván Peñuelas, John Seibyl, Franck Semah, Livia Tossici-Bolt, Elsmarieke Van de Giessen, Koen Van Laere, Andrea Varrone, Michele Wanner, George Zubal, Ian Law

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 8/2020

Abstract

Purpose

This joint practice guideline or procedure standard was developed collaboratively by the European Association of Nuclear Medicine (EANM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). The goal of this guideline is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of dopaminergic imaging in parkinsonian syndromes.

Methods

Currently nuclear medicine investigations can assess both presynaptic and postsynaptic function of dopaminergic synapses. To date both EANM and SNMMI have published procedural guidelines for dopamine transporter imaging with single photon emission computed tomography (SPECT) (in 2009 and 2011, respectively). An EANM guideline for D2 SPECT imaging is also available (2009). Since the publication of these previous guidelines, new lines of evidence have been made available on semiquantification, harmonization, comparison with normal datasets, and longitudinal analyses of dopamine transporter imaging with SPECT. Similarly, details on acquisition protocols and simplified quantification methods are now available for dopamine transporter imaging with PET, including recently developed fluorinated tracers. Finally, [¹⁸F]fluorodopa PET is now used in some centers for the differential diagnosis of parkinsonism, although procedural guidelines aiming to define standard procedures for [¹⁸F]fluorodopa imaging in this setting are still lacking.

Conclusion

All these emerging issues are addressed in the present procedural guidelines for dopaminergic imaging in parkinsonian syndromes.

Berardelli A, Wenning GK, Antonini A, Berg D, Bloem BR, Bonifati V, et al. EFNS/MDS-ES/ENS recommendations for the diagnosis of Parkinson's disease. Eur J Neurol. 2013;20:16–34.PubMedCrossRef

Martí MJ, Tolosa E, Campdelacreu J. Clinical overview of the synucleinopathies. Mov Disord. 2003;18(Suppl 6):S21–7.PubMedCrossRef

Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80:496–503.PubMedPubMedCentralCrossRef

Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, et al. Movement Disorder Society-endorsed PSP Study Group. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32:853–64.PubMedPubMedCentralCrossRef

Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathologic study. Neurology. 2001;57(suppl 3):S34–8.PubMed

Booij J, Knol RJ. SPECT imaging of the dopaminergic system in (premotor) Parkinson’s disease. Parkinsonism Relat Disorders. 2007;13(Suppl 3):S425–8.CrossRef

Elsinga PH, Hatano K, Ishiwata K. PET tracers for imaging of the dopaminergic system. Curr Med Chem. 2006;13:2139–53.PubMedCrossRef

Thobois S, Jahanshahi M, Pinto S, Frackowiak R, Limousin DP. PET and SPECT functional imaging studies in Parkinsonian syndromes: from the lesion to its consequences. Neuroimage. 2004;23:1–16.PubMedCrossRef

Van Laere K, Varrone A, Booij J, Vander Borght T, Nobili F, Kapucu OL, et al. EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2. Eur J Nucl Med Mol Imaging. 2010;37:434–42.PubMedCrossRef

10.

Kim YJ, Ichise M, Ballinger JR, Vines D, Erami SS, Tatschida T, et al. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord. 2002;17:303–12.PubMedCrossRef

11.

Darcourt J, Booij J, Tatsch K, Varrone A, Vander Borght T, Kapucu OL, et al. EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging. 2010;37:443–50.PubMedCrossRef

12.

Djang DS, Janssen MJ, Bohnen N, Booij J, Henderson TA, Herholz K, et al. SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0. J Nucl Med. 2012;53:154–63.PubMedCrossRef

13.

DaTSCAN European Public Assessment Report. 072200en6.pdf and DaTSCAN-H-266-AR-II.pdf. https://www.ema.europa.eu/en/medicines/human/EPAR/datscan. Accessed 25 Jul 2019.

14.

Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord. 2000;15:503–10.PubMedCrossRef

15.

Booij J, Hemelaar TG, Speelman JD, de Bruin K, Janssen AG, van Royen EA. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson’s disease by [123I]FPCIT SPECT. J Nucl Med. 1999;40:753–61.PubMed

16.

Scherfler C, Schwarz J, Antonini A, Grosset D, Valldeoriola F, Marek K, et al. Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord. 2007;22:1229–38.PubMedCrossRef

17.

Nicastro N, Garibotto V, Burkhard PR. 123I-FP-CIT SPECT accurately distinguishes parkinsonian from cerebellar variant of multiple system atrophy. Clin Nucl Med. 2018;43:33–6.CrossRef

18.

McKeith I, O’Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6:305–13.PubMedCrossRef

19.

Thomas AJ, Attems J, Colloby SJ, O'Brien JT, McKeith I, Walker R, et al. Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB. Neurology. 2017;88:276–83.PubMedPubMedCentralCrossRef

20.

McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89:88–100.PubMedPubMedCentralCrossRef

21.

Lorberboym M, Treves TA, Melamed E, Lampl Y, Hellmann M, Djaldetti R. [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson’s disease. Mov Disord. 2006;21:510–4.PubMedCrossRef

22.

Felicio AC, Godeiro-Junior C, Moriyama TS, Shih MC, Hoexter MQ, Borges V, et al. Degenerative parkinsonism in patients with psychogenic parkinsonism: a dopamine transporter imaging study. Clin Neurol Neurosurg. 2010;112:282–5.PubMedCrossRef

23.

Brigo F, Matinella A, Erro R, Tinazzi M. [¹²³I]FP-CIT SPECT (DaTSCAN) may be a useful tool to differentiate between Parkinson's disease and vascular or drug-induced parkinsonisms: a meta-analysis. Eur J Neurol. 2014:21, 1369–1390.

24.

Bauckneht M, Chincarini A, De Carli F, Terzaghi M, Morbelli S, Nobili F, et al. Presynaptic dopaminergic neuroimaging in REM sleep behavior disorder: a systematic review and meta-analysis. Sleep Med Rev. 2018;41:266–74.PubMedCrossRef

25.

Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, et al. MDS research criteria for prodromal Parkinson's disease. Mov Disord. 2015;30:1600–11.CrossRefPubMed

26.

Schreckenberger M, Hagele S, Siessmeier T, Buchholz HG, Armbrust-Henrich H, Rösch F, et al. The dopamine D2 receptor ligand 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism. Eur J Nucl Med Mol Imaging. 2004;31:1128–35.PubMedCrossRef

27.

Hellwig S, Amtage F, Kreft A, Buchert R, Winz OH, Vach W, et al. [¹⁸F]FDG-PET is superior to [¹²³I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology. 2012;79:1314–22.PubMedCrossRef

28.

Yoshita M. Differentiation of idiopathic Parkinson’s disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci. 1998;155:60–7.PubMedCrossRef

29.

FDA. Highlights of prescribing information F-DOPA. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/200655s000lbl.pdf Accessed 10 Oct 2019.

30.

Kaasinen V, Vahlberg T. Striatal dopamine in Parkinson disease: a meta-analysis of imaging studies. Ann Neurol. 2017;82:873–82.PubMedCrossRef

31.

Ribeiro MJ, Vidailhet M, Loc'h C, Dupel C, Nguyen JP, Ponchant M, et al. Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease. Arch Neurol. 2002;59:580–6.PubMedCrossRef

32.

Eshuis SA, Maguire RP, Leenders KL, Jonkman S, Jager PL. Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson's disease. Eur J Nucl Med Mol Imaging. 2006;33:200–9.PubMedCrossRef

33.

Booij J, Kemp P. Dopamine transporter imaging with [(123)I]FPCIT SPECT: potential effects of drugs. Eur J Nucl Med Mol Imaging. 2008;35:424–38.PubMedCrossRef

34.

Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, Telang F, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA. 2009;301:1148–54.PubMedPubMedCentralCrossRef

35.

Iffland K, Grotenhermen F. An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis Cannabinoid Res. 2017;2:139–54.PubMedPubMedCentralCrossRef

36.

Booij J, de Jong J, de Bruin K, Knol RJJ, de Win MM, van Eck-Smit BLF. Quantification of striatal dopamine transporters with [123I]FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy controls. J Nucl Med. 2007;48:359–66.PubMed

37.

Cilia R, Marotta G, Belletti A, Siri C, Pezzoli G. Reversible dopamine transporter reduction in drug-induced parkinsonism. Mov Disord. 2014;29:575–746.PubMedCrossRef

38.

Schillaci O, Pierantozzi M, Filippi L, Manni C, Brusa L, Danieli R, et al. The effect of levodopa therapy on dopamine transporter SPECT imaging with 123I-FP-CIT in patients with Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2005;32:1452–6.PubMedCrossRef

39.

Yang YK, Yao WJ, Yeh TL, Lee IH, Chen PS, Lu RB, et al. Decreased dopamine transporter availability in male smokers-a dual isotope SPECT study. Prog Neuro-Psychopharmacol Biol Psychiatry. 2008;32:274–9.CrossRef

40.

Seibyl JP, Wallace E, Smith EO, Stabin M, Baldwin RM, Zoghbi S, et al. Whole-body biodistribution, radiation absorbed dose and brain SPECT imaging with iodine-123-beta-CIT in healthy human subjects. J Nucl Med. 1994;35:764–70.PubMed

41.

Varrone A, Sansone V, Pellecchia MT, Amboni M, Salvatore E, De Michele G, et al. Comparison between a dual-head and a brain-dedicated SPECT system in the measurement of the loss of dopamine transporters with [(123)I]FP-CIT. Eur J Nucl Med Mol Imaging. 2008;35:1343–9.PubMedCrossRef

42.

Dobbeleir AA, Hambÿe A-SE, Franken PR. Influence of high-energy photons on the spectrum of iodine-123 with low-and medium-energy collimators: consequences for imaging with 123Ilabelled compounds in clinical practice. Eur J Nucl Med Mol Imaging. 1999;26:655–8.CrossRef

43.

Koch W, Bartenstein P, la Fougère C. Radius dependence of FP-CIT quantification: a Monte Carlo-based simulation study. Ann Nuc Med. 2014;28:103–11.CrossRef

44.

QIBA Profile: Quantifying dopamine transporters with 123 - iodine labeled ioflupane in neurodegenerative disease profile (v1.1), August 28, 2017.

45.

Dickson JC, Tossici-Bolt L, Sera T, Erlandsson K, Varrone A, Tatsch K, et al. The impact of reconstruction method on the quantification of DaTSCAN images. Eur J Nucl Med Mol Imaging. 2010;37:23–35.PubMedCrossRef

46.

Tossici-Bolt L, Dickson JC, Sera T, de Nijs R, Bagnara MC, Jonsson C, et al. Calibration of gamma camera systems for a multicentre European 123I-FP-CIT SPECT normal database. Eur J Nucl Med Mol Imaging. 2011;38:1529–40.PubMedCrossRef

47.

Soret M, Koulibaly PM, Darcourt J, Hapdey S, Buvat I. Quantitative accuracy of dopaminergic neurotransmission imaging with (123)I SPECT. J Nuc Med. 2003;44:1184–93.

48.

Ichihara T, Ogawa K, Motomura N, Kubo A, Hashimoto S. Compton scatter compensation using the triple-energy window method for single- and dual-isotope SPECT. J Nuc Med. 1993;34:2216–21.

49.

Iida H, Narita Y, Kado H, Kashikura A, Sugawara S, Shoji Y, et al. Effects of scatter and attenuation correction on quantitative assessment of regional cerebral blood flow with SPECT. J Nucl Med. 1998;39:181–9.PubMed

50.

Tossici-Bolt L, Dickson JC, Sera T, Booij J, Asenbaun-Nan S, Bagnara MC, et al. [(123)I]FP-CIT ENC-DAT normal database: the impact of the reconstruction and quantification methods. EJNMMI Physics. 2017;4:8.PubMedPubMedCentralCrossRef

51.

EANM Physics Committee Busemann Sokole E, Płachcínska A, Britten A; EANM Working Group on. Routine quality control recommendations for nuclear medicine instrumentation. Eur J Nuc Med Mol imaging. 2010;37:662–71.CrossRef

52.

Booij J, Dubroff J, Pryma D, Yu J, Agarwal R, Lakhani P, et al. Diagnostic performance of the visual reading of (123)I-ioflupane SPECT images with or without quantification in patients with movement disorders or dementia. J Nucl Med. 2017;58:1821–6.PubMedCrossRef

53.

INTERNATIONAL ATOMIC ENERGY AGENCY, Quality assurance for SPECT systems, IAEA Human Health Series No. 6, IAEA, Vienna (2009).

54.

INTERNATIONAL ATOMIC ENERGY AGENCY, Quality assurance programme for computed tomography: diagnostic and therapy applications, IAEA Human Health Series No. 19, IAEA, Vienna (2012).

55.

Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AG, van Royen EA, et al. Iodine-123-N-omega-fluoropropyl-2 bcarbomethoxy-3 b-(4-iodophenyl)tropane SPECT in healthy controls and early stage, drug-naive Parkinson’s disease. J Nucl Med. 1998;39:1143–8.PubMed

56.

Marshall VL, Reininger CB, Marquardt M, Patterson J, Hadley DM, Oertel WH, et al. Parkinson’s disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord. 2009;24:500–8.PubMedCrossRef

57.

Catafau AM, Tolosa E, DaTSCAN Clinically Uncertain Parkinsonian Syndromes Study Group. Impact of dopamine transporter SPECT using 123I-ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes. Mov Disord. 2004;19:1175–82.PubMedCrossRef

58.

Arnaldi D, De Carli F, Picco A, Ferrara M, Accardo J, Bossert I, et al. Nigro-caudate dopaminergic deafferentation: a marker of REM sleep behavior disorder? Neurobiol Aging. 2015;36:3300–5.PubMedCrossRef

59.

Pirker W, Holler I, Gerschlager W, Asenbaum S, Zettinig G, Brücke T. Measuring the rate of progression of Parkinson's disease over a 5-year period with beta-CIT SPECT. Mov Disord. 2003;18:1266–72.PubMedCrossRef

60.

Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain. 2013;136:2419–31.PubMedPubMedCentralCrossRef

61.

Marek K, Seibyl J, Eberly S, Oakes D, Shoulson I, Lang AE, et al. Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. Neurology. 2014;82:1791–7.PubMedPubMedCentralCrossRef

62.

Lorberboym M, Djaldetti R, Melamed E, Sadeh M, Lampl Y. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. J Nucl Med. 2004;45:1688–93.PubMed

63.

Benítez-Rivero S, Marín-Oyaga VA, García-Solís D, Huertas-Fernández I, García-Gómez FJ, Jesús S, et al. Clinical features and 123I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson's disease. J Neurol Neurosurg Psychiatry. 2013;84:122–9.PubMedCrossRef

64.

Vizcarra JA, Lang AE, Sethi KD, Espay AJ. Vascular parkinsonism: deconstructing a syndrome. Mov Disord. 2015;30:886–94.PubMedPubMedCentralCrossRef

65.

Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12:822–38.PubMedPubMedCentralCrossRef

66.

Jellinger KA. The neuropathologic diagnosis of secondary parkinsonian syndromes. Adv Neurol. 1996;69:293–303.PubMed

67.

Van der Zande J, Booij J, Scheltens P, Raijmakers P, Lemstra AW. [123]FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodies. Eur J Nucl Med Mol Imaging. 2016;43:1060–6.PubMedPubMedCentralCrossRef

68.

Nobili F, Arnaldi D, Morbelli S. Is dopamine transporter invariably impaired at the time of diagnosis in dementia with Lewy bodies? Eur J Nucl Med Mol Imaging. 2016;43:1056–9.PubMedCrossRef

69.

Cilia R, Rossi C, Frosini D, Volterrani D, Siri C, Pagni C, et al. Dopamine transporter SPECT imaging in corticobasal syndrome. PLoS One. 2011;6:18301.CrossRef

70.

Walker Z, Gandolfo F, Orini S, Garibotto V, Agosta F, Arbizu J, et al. Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia. Eur J Nucl Med Mol Imaging. 2018;45:1534–45.PubMedPubMedCentralCrossRef

71.

Orimo S, Suzuki M, Inaba A, Mizusawa H. 123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2012;18:494–500.PubMedCrossRef

72.

Rinne JO, Laine M, Kaasinen V, Norvasuo-Heilä MK, Någren K, Helenius H. Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia. Neurology. 2002;58:1489–93.PubMedCrossRef

73.

Morgan S, Kemp P, Booij J, Costa DC, Padayachee S, Lee L, et al. Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT. J Neurol Neurosurg Psychiatry. 2012;83:1063–70.PubMedCrossRef

74.

Miyoshi M, Shinotoh H, Wszolek ZK, Strongosky AJ, Shimada H, Arakawa R, et al. In vivo detection of neuropathologic changes in presymptomatic MAPT mutation carriers: a PET and MRI study. Parkinsonism Relat Disord. 2010;16:404–8.PubMedCrossRef

75.

Kishore A, Wszolek ZK, Snow BJ, de la Fuente-Fernandez R, Arwert F, Wijker M, et al. Presynaptic nigrostriatal function in genetically tested asymptomatic relatives from the pallido-ponto-nigral degeneration family. Neurology. 1996;47:1588–90.PubMedCrossRef

76.

Tiraboschi P, Corso A, Guerra UP, Nobili F, Piccardo A, Calcagni ML, et al. 123 I-FP-CIT SPECT and 123 I-MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from other dementias: a comparative study. Ann Neurol. 2016;80:368–78.PubMedCrossRef

77.

Arnaldi D, Campus C, Ferrara M, Famà F, Picco A, De Carli F, et al. What predicts cognitive decline in de novo Parkinson's disease? Neurobiol Aging. 2012;1127:11–20.

78.

Seibyl JP, Marek K, Sheff K, Zoghbi S, Baldwin RM, Charney DS, et al. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson’s patients. J Nucl Med. 1998;39:1500–8.PubMed

79.

Laruelle M, Wallace E, Seibyl JP, Baldwin RM, Zea-Ponce Y, Zoghbi SS, et al. Graphical, kinetic, and equilibrium analyses of in vivo [123I] beta-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab. 1994;14:982–94.PubMedCrossRef

80.

Seibyl JP, Marek K, Sheff K, Baldwin RM, Zoghbi S, Zea-Ponce Y, et al. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients. J Nucl Med. 1997;38:1453–9.PubMed

81.

Booij J, Dubroff J, Pryma D, Yu JQ, Agarwal R, Lakhani P, et al. Diagnostic performance of the visual reading of (123)I-ioflupane SPECT images when assessed with or without quantification in patients with movement disorders or dementia. J Nuc Med. 2017;58:1821–6.CrossRef

82.

Booij J, Habraken JB, Bergmans P, Tissingh G, Winogrodzka A, Wolters EC, et al. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson’s disease. J Nucl Med. 1998;39:1879–84.PubMed

83.

Calvini P, Rodriguez G, Inguglia F, Mignone A, Guerra UP, Nobili F. The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation. Eur J Nucl Med Mol Imaging. 2007;34:1240–53.PubMedCrossRef

84.

Matesan M, Gaddikeri S, Longfellow K, Miyaoka R, Elojeimy S, Elman S, et al. I-123 DaTscan SPECT brain imaging in Parkinsonian syndromes: utility of the putamen-to-caudate ratio. J Neuroimaging. 2018;28:629–34.PubMedCrossRef

85.

Zubal IG, Early M, Yuan O, Jennings D, Marek K, Seibyl JP. Optimized, automated striatal uptake analysis applied to SPECT brain scans of Parkinson's disease patients. J Nucl Med. 2007;48:857–64.PubMedCrossRef

86.

Morton RJ, Guy MJ, Clauss R, Hinton PJ, Marshall CA, Clarke EA. Comparison of different methods of DatSCAN quantification. Nucl Med Commun. 2005;26:1139–46.PubMedCrossRef

87.

Nobili F, Naseri M, De Carli F, Asenbaum S, Booij J, Darcourt J, et al. Automatic semi-quantification of [123I]FP-CIT SPECT scans in healthy volunteers using BasGan version 2: results from the ENC-DAT database. Eur J Nucl Med Mol Imaging. 2013;40:565–7.PubMedCrossRef

88.

Kuo PH, Lei HH, Avery R, Krupinski EA, Bauer A, Sherman S, et al. Evaluation of an objective striatal analysis program for determining laterality in uptake of ¹²³I-ioflupane SPECT images: comparison to clinical symptoms and to visual reads. J Nucl Med Technol. 2014;42:105–8.PubMedCrossRef

89.

90.

Koch W, Radau PE, Munzing W, Tatsch K. Cross-camera comparison of SPECT measurements of a 3-D anthropomorphic basal ganglia phantom. Eur J Nucl Med Mol Imaging. 2006;33:495–502.PubMedCrossRef

91.

Tinaz S, Chow C, Kuo PH, Krupinski EA, Blumenfeld H, Louis ED, et al. Semiquantitative analysis of dopamine transporter scans in patients with Parkinson disease. Clin Nucl Med. 2018;43:1–7.CrossRef

92.

Kuo PH, Eshghi N, Tinaz S, Blumenfeld H, Louis ED, Zubal G. Optimization of parameters for quantitative analysis of 123I-ioflupane SPECT images for monitoring of progression of Parkinson's disease. J Nucl Med Technol. 2019;47:70–4.PubMedCrossRef

93.

Tossici-Bolt L, Hoffmann SM, Kemp PM, Mehta RL, Fleming JS. Quantification of [(123)I]FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio. Eur J Nucl Med Mol Imaging. 2006;33:1491–9.PubMedCrossRef

94.

Hsu CC, Chang YH, Lin WC, Tang SW, Wang PW, Huang YC, et al. The feasibility of using CT-guided ROI for semiquantifying striatal dopamine transporter availability in a hybrid SPECT/CT system. ScientificWorldJournal. 2014;2014:879497.PubMedPubMedCentral

95.

Hirschauer TJ, Adeli H. JA Buford Computer-aided diagnosis of Parkinson's disease using enhanced probabilistic neural network. J Med Syst. 2015;39:179.PubMedCrossRef

96.

Rahmim A, Salimpour Y, Jain S, Blinder SA, Klyuzhin IS, Smith GS, et al. Application of texture analysis to DAT SPECT imaging: relationship to clinical assessments. Neuroimage Clin. 2016;12:1–9.CrossRef

97.

Mozley PD, Schneider JS, Acton PD, Plössl K, Stern MB, Siderowf A, et al. Binding of [99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers. J Nucl Med. 2000;41:584–9.PubMed

98.

Dickson JC, Tossici-Bolt L, Sera T, Booij J, Ziebell M, Morbelli S, et al. The impact of reconstruction and scanner characterization on the diagnostic capability of a normal database for [(123)I]FP-CIT SPECT imaging. EJNMMI Res. 2017;7:10.PubMedPubMedCentralCrossRef

99.

Buchert R, Kluge A, Tossici-Bolt L, Dickson J, Bronzel M, Lange C, et al. Reduction in camera-specific variability in [(123)I]FP-CIT SPECT outcome measures by image reconstruction optimized for multisite settings: impact on age-dependence of the specific binding ratio in the ENC-DAT database of healthy controls. Eur J Nucl Med Mol Imaging. 2016;43:1323–36.PubMedCrossRef

100.

Varrone A, Dickson JC, Tossici-Bolt L, Sera T, Asenbaum S, Booij J, et al. European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging. 2013;40:213–27.CrossRefPubMed

101.

Parkinson Progression Marker Initiative. The Parkinson progression marker initiative (PPMI). Prog Neurobiol. 2011;95:629–35.CrossRef

102.

Hesse S, van de Giessen E, Zientek F, Petroff D, Winter K, Dickson JC, et al. Association of central serotonin transporter availability and body mass index in healthy Europeans. Eur Neuropsychopharmacol. 2014;24:1240–7.PubMedCrossRef

103.

Lapa C, Spehl TS, Brumberg J, Isaias IU, Schlögl S, Lassmann M, et al. Influence of CT-based attenuation correction on dopamine transporter SPECT with [(123)I]FP-CIT. Am J Nucl Med Mol Imaging. 2015;5:278–86.PubMedPubMedCentral

104.

Simuni T, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Jennings D, et al. Longitudinal change of clinical and biological measures in early Parkinson's disease: Parkinson's progression markers initiative cohort. Mov Disord. 2018;33:771–82.PubMedPubMedCentralCrossRef

105.

Dickson JC, Tossici-Bolt L, Sera T, de Nijs R, Booij J, Bagnara MC, et al. Proposal for the standardisation of multi-centre trials in nuclear medicine imaging: prerequisites for a European 123I-FP-CIT SPECT database. Eur J Nucl Med Mol Imaging. 2011;39:188–97.CrossRef

106.

Gründer G, Vernaleken I, Müller MJ, Davids E, Heydari N, Buchholz HG, et al. Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo. Neuropsychopharmacology. 2003;28:787–94.PubMedCrossRef

107.

Stout DB, Huang SC, Melega WP, Raleigh MJ, Phelps ME, Barrio JR. Effects of large neutral amino acid concentrations on 6-[F-18]Fluoro-L-DOPA kinetics. J Cereb Blood Flow Metab. 1998;18:43–51.PubMedCrossRef

108.

Bloomfield MA, Pepper F, Egerton A, Demjaha A, Tomasi G, Mouchlianitis E, et al. Dopamine function in cigarette smokers: an [¹⁸F]-DOPA PET study. Neuropsychopharmacology. 2014;39:2397–404.PubMedPubMedCentralCrossRef

109.

Cumming P, Ase A, Diksic M, Harrison J, Jolly D, Kuwabara H, et al. Metabolism and blood-brain clearance of L-3,4-dihydroxy-[3H]phenylalanine ([3H]DOPA) and 6-[18F]fluoro-L-DOPA in the rat. Biochem Pharmacol. 1995;50:943–6.PubMedCrossRef

110.

Brown WD, Oakes TR, DeJesus OT, Taylor MD, Roberts AD, Nickles RJ, et al. Fluorine-18-fluoro-L-DOPA dosimetry with carbidopa pretreatment. J Nucl Med. 1998;39:1884–91.PubMed

111.

Sawle GV, Burn DJ, Morrish PK, Lammertsma AA, Snow BJ, Luthra S, et al. The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease. Neurology. 1994;44:1292–7.PubMedCrossRef

112.

Dhawan V, Ma Y, Pillai V, Spetsieris P, Chaly T, Belakhlef A, et al. Comparative analysis of striatal FDOPA uptake in Parkinson's disease: ratio method versus graphical approach. J Nucl Med. 2002;43:1324–30.PubMed

113.

Darcourt J, Schiazza A, Sapin N, Dufour M, Ouvrier MJ, Benisvy D, et al. 18F-FDOPA PET for the diagnosis of parkinsonian syndromes. Q J Nucl Med Mol Imaging. 2014;58:355–65.PubMed

114.

Jokinen P, Helenius H, Rauhala E, Brück A, Eskola O, Rinne JO. Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls. J Nucl Med. 2009;50:893–9.PubMedCrossRef

115.

Darcourt J, Schiazza A, Sapin N, Dufour M, Ouvrier MJ, Benisvy D, et al. 18F-FDOPA PET for the diagnosis of parkinsonian syndromes. Q J Nucl Med Mol Imaging. 2014;58:355–65.PubMed

116.

Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol. 2003;54:93–101.PubMedCrossRef

117.

Nagaki A, Onoguchi M, Matsutomo N. Clinical validation of high-resolution image reconstruction algorithms in brain 18F-FDG-PET: effect of incorporating Gaussian filter, point spread function, and time-of-flight. Nucl Med Commun. 2014;35:1224–32.PubMedCrossRef

118.

Prieto E, Martí-Climent JM, Morán V, Sancho L, Barbés B, Arbizu J, et al. Brain PET imaging optimization with time of flight and point spread function modelling. Phys Med. 2015;31:948–55.PubMedCrossRef

119.

Erlandsson K, Buvat I, Pretorius PH, Thomas BA, Hutton BF. A review of partial volume correction techniques for emission tomography and their applications in neurology, cardiology and oncology. Phys Med Biol. 2012;57:119–59.CrossRef

120.

Rahmim A, Qi J, Sossi V. Resolution modeling in PET imaging: theory, practice, benefits, and pitfalls. Med Phys. 2013;40:064301.PubMedPubMedCentralCrossRef

121.

Sawle GV, Playford ED, Burn DJ, Cunningham VJ, Henderson BT, Brooks DJ. Separating Parkinson’s disease from normality: discriminant function analysis of [18F]Dopa PET data. Arch.Neurol. 1994;51:237–43.PubMedCrossRef

122.

Takikawa S, Dhawan V, Chaly T, Robeson W, Dahl R, Zanzi I, et al. Input functions for 6-[fluorine-18]fluorodopa quantitation in parkinsonism: comparative studies and clinical correlations. J Nucl Med. 1994;35:955–63.PubMed

123.

Pavese N, Rivero-Bosch M, Lewis SJ, Whone AL, Brooks DJ. Progression of monoaminergic dysfunction in Parkinson's disease: a longitudinal 18F-dopa PET study. NeuroImage. 2011;56:1463–8.PubMedCrossRef

124.

Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J.Cereb.Blood.Flow.Metab. 1983;3:1–7.PubMedCrossRef

125.

Brown RM, Crane AM, Goldman PS. Regional distribution of monoamines in the cerebral cortex and subcortical structures of the rhesus monkey: concentrations and in vivo synthesis rates. Brain Res. 1979;168:133–50.PubMedCrossRef

126.

Brooks DJ, Ibañez V, Sawle GV, Quinn N, Lees AJ, Mathias CJ, et al. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Ann.Neurol. 1990;28:547–55.PubMedCrossRef

127.

Sossi V, de La Fuente-Fernandez R, Holden JE, Doudet DJ, McKenzie J, Stoessl AJ, et al. Increase in dopamine turnover occurs early in Parkinson's disease: evidence from a new modeling approach to PET 18 F-fluorodopa data. J Cereb Blood Flow Metab. 2002;22:232–9.PubMedCrossRef

128.

Kumakura Y, Cumming P, Vernaleken I, Buchholz HG, Siessmeier T, Heinz A, et al. Elevated [18F]fluorodopamine turnover in brain of patients with schizophrenia: an [18F]fluorodopa/positron emission tomography study. J Neurosci. 2007;27:8080–7.PubMedPubMedCentralCrossRef

129.

Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181–200.PubMedCrossRef

130.

Varrone A, Halldin C. New developments of dopaminergic imaging in Parkinson’s disease. Q J Nucl Med Mol Imaging. 2012;56:68–82.PubMed

131.

Halldin C, Erixon-Lindroth N, Pauli S, Chou YH, Okubo Y, Karlsson P, et al. [11C]PE21: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain. Eur J Nucl Med Mol Imaging. 2003;30:1220–30.PubMedCrossRef

132.

Jucaite A, Odano I, Olsson H, Pauli S, Halldin C, Farde L. Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: a PET study. Eur J Nucl Med Mol Imaging. 2006;33:657–68.PubMedCrossRef

133.

Hirvonen J, Johansson J, Teräs M, Oikonen V, Lumme V, Virsu P, et al. Measurement of striatal and extrastriatal dopamine transporter binding with high-resolution PET and [11C]PE2I: quantitative modeling and test-retest reproducibility. J Cereb Blood Flow Metab. 2008;28:1059–69.PubMedCrossRef

134.

Paul G, Zachrisson O, Varrone A, Almqvist P, Jerling M, Lind G, et al. Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson’s disease patients. J Clin Invest. 2015;125:1339–46.PubMedPubMedCentralCrossRef

135.

Appel L, Jonasson M, Danfors T, Nyholm D, Askmark H, Lubberink M, et al. Use of 11C-PE2I PET in differential diagnosis of Parkinsonian disorders. J Nucl Med. 2015;56:234–42.PubMedCrossRef

136.

Li W, Lao-Kaim NP, Roussakis AA, Martín-Bastida A, Valle-Guzman N, Paul G, et al. 11C-PE2I and18F-Dopa PET for assessing progression rate in Parkinson’s: a longitudinal study. Mov Disord. 2018;33:117–27.PubMedCrossRef

137.

Inaji M, Okauchi T, Ando K, Maeda J, Nagai Y, Yoshizaki T, et al. Correlation between quantitative imaging and behavior in unilaterally 6-OHDA-lesioned rats. Brain Res. 2005;1064:136–45.PubMedCrossRef

138.

Aznavour N, Cendres-Bozzi C, Lemoine L, Buda C, Sastre JP, Mincheva Z, et al. MPTP animal model of parkinsonism: dopamine cell death or only tyrosine hydroxylase impairment? - a study using PET imaging, autoradiography, and immunohistochemistry in the cat. CNS Neurosci Ther. 2012;18:934–41.PubMedPubMedCentralCrossRef

139.

DeLorenzo C, Kumar JD, Zanderigo F, Mann JJ, Parsey RV. Modeling considerations for in vivo quantification of the dopamine transporter using 11 CPE2I and positron emission tomography. J Cereb Blood Flow Metab. 2009;29:1332–45.PubMedCrossRef

140.

Varrone A, Steiger C, Schou M, Takano A, Finnema SJ, Guilloteau D, et al. In vitro autoradiography and in vivo evaluation in cynomolgus monkey of [18F]FE-PE2I, a new dopamine transporter PET radioligand. Synapse. 2009;63:871–80.PubMedCrossRef

141.

Varrone A, Toth M, Steiger C, Takano A, Guilloteau D, Ichise M, et al. Kinetic analysis and quantification of the dopamine transporter in the nonhuman primate brain with 11C-PE2I and 18F-FE-PE2I. J Nucl Med. 2011;52:132–9.PubMedCrossRef

142.

Sasaki T, Ito H, Kimura Y, Arakawa R, Takano H, Seki C, et al. Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I. J Nucl Med. 2012;53:1065–73.PubMedCrossRef

143.

Fazio P, Svenningsson P, Forsberg A, Jonsson EG, Amini N, Nakao R, et al. Quantitative analysis of (1)(8)F-(E)-N-(3-iodoprop-2-enyl)-2beta-carbofluoroethoxy-3beta-(4′-methyl-phenyl ) nortropane binding to the dopamine transporter in Parkinson disease. J Nucl Med. 2015;56:714–20.CrossRefPubMed

144.

Sonni I, Fazio P, Schain M, Halldin C, Svenningsson P, Farde L, et al. Optimal acquisition time window and simplified quantification of dopamine transporter availability using 18F-FE-PE2I in healthy controls and Parkinson disease patients. J Nucl Med. 2016;57:1529–34.CrossRefPubMed

145.

Fazio P, Svenningsson P, Cselenyi Z, Halldin C, Farde L, Varrone A. Nigrostriatal dopamine transporter availability in early Parkinson's disease. Mov Disord. 2018;33:592–9.CrossRefPubMed

146.

Varrone A, Gulyas B, Takano A, Stabin MG, Jonsson C, Halldin C. Simplified quantification and whole-body distribution of [18F]FE-PE2I in nonhuman primates: prediction for human studies. Nucl Med Biol. 2012;39:295–303.PubMedCrossRef

147.

Lizana H, Johansson L, Axelsson J, Larsson A, Ogren M, Linder J, et al. Whole-body biodistribution and dosimetry of the dopamine transporter radioligand (18)F-FE-PE2I in human subjects. J Nucl Med. 2018;59:1275–80.PubMedCrossRef

148.

Jakobson Mo S, Axelsson J, Jonasson L, Larsson A, Ögren MJ, Ögren M, et al. Dopamine transporter imaging with [18F]FE-PE2I PET and [123I]FP-CIT SPECT-a clinical comparison. EJNMMI Res. 2018;8:100.PubMedPubMedCentralCrossRef

149.

Erickson JD, Eiden LE. Functional identification and molecular cloning of a human brain vescile monoamine transporter. J Neurochem. 1993;61:2314–7.PubMedCrossRef

150.

Scherman D, Raisman R, Ploska A, Agid Y. [3H]Dihydrotetrabenazine, a new in vitro monoaminergic probe for human brain. J Neurochem. 1988;50:1131–6.PubMedCrossRef

151.

Schafer MK, Hartwig NR, Kalmbach N, Klietz M, Anlauf M, Eiden LE, et al. Species-specific vesicular monoamine transporter 2 (VMAT2) expression in mammalian pancreatic beta cells: implications for optimising radioligand-based human beta cell mass (BCM) imaging in animal models. Diabetologia. 2013;56(5):1047–56.PubMedPubMedCentralCrossRef

152.

Vander Borght TM, Sima AA, Kilbourn MR, Desmond TJ, Kuhl DE, Frey KA. [3H]methoxytetrabenazine: a high specific activity ligand for estimating monoaminergic neuronal integrity. Neuroscience. 1995;68:955–62.PubMedCrossRef

153.

Frey KA, Koeppe RA, Kilbourn MR, Vander Borght TM, Albin RL, Gilman S, et al. Presynaptic monoaminergic vesicles in Parkinson’s disease and normal aging. Ann Neurol. 1996;40:873–84.PubMedCrossRef

154.

Bohnen NI, Albin RL, Koeppe RA, Wernette KA, Kilbourn MR, Minoshima S, et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab. 2006;26:1198–212.PubMedCrossRef

155.

Lin KJ, Weng YH, Wey SP, Hsiao IT, Lu CS, Skovronsky D, et al. Whole-body biodistribution and radiation dosimetry of 18F-FP-(+)-DTBZ (18F-AV-133): a novel vesicular monoamine transporter 2 imaging agent. J Nucl Med. 2010;51:1480–5.PubMedCrossRef

156.

Lin KJ, Lin WY, Hsieh CJ, Weng YH, Wey SP, Lu CS, et al. Optimal scanning time window for 18F-FP-(+)-DTBZ (18F-AV-133) summed uptake measurements. Nucl Med Biol. 2011;38:1149–55.PubMedCrossRef

157.

Lin KJ, Weng YH, Hsieh CJ, Lin WY, Wey SP, Kung MP, et al. Brain imaging of vesicular monoamine transporter type 2 in healthy aging subjects by 18F-FP-(+)-DTBZ PET. PLoS One. 2013;8:75952.CrossRef

158.

Halldin C, Gulyas B, Langer O, Farde L. Brain radioligands –state of the art and new trends. Q J Nucl Med. 2001;45:139–52.PubMed

159.

Pinborg LH, Videbaek C, Knudsen GM, Swahn CG, Halldin C, Friberg L, et al. Dopamine D(2) receptor quantification in extrastriatal brain regions using [(123)I] epidepride with bolus/infusion. Synapse. 2000;36:322–9.PubMedCrossRef

160.

Treglia G, Cason E, Stefanelli A, Cocciolillo F, Di Giuda D, Fagioli G, et al. MIBG scintigraphy in differential diagnosis of parkinsonism: a meta-analysis. Clin Auton Res. 2012;22:43–55.PubMedCrossRef

161.

EU BSS Directive. Council Directive 2013/59/Euratom of 5 december 2013.

162.

IAEA Safety Guide. Radiation Protection and Safety in Medical Uses of Ionizing Radiation. Specific Safety Guide SSG-46, IAEA, Vienna 2018.

163.

Kuikka JT, Bergström KA, Ahonen A, Länsimies E. The dosimetry of iodine-123 labelled 2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane. Eur J Nucl Med. 1994;21:53–6.PubMed

164.

Kuikka JT. Dosimetry of iodine-123-beta-CIT. J Nucl Med. 1995;36:711.PubMed

165.

Mattsson S, Johansson L, Leide Svegborn S, Liniecki J, Noßke D, Riklund KÅ, et al. Radiation dose to patients from radiopharmaceuticals: a compendium of current information related to frequently used substances. Ann ICRP. 2015;44(2 Suppl):7–321.PubMedCrossRef

166.

Mozley PD, Stubbs JB, Plössl K, Dresel SH, Barraclough ED, Alavi A, et al. Biodistribution and dosimetry of TRODAT-1: a technetium-99m tropane for imaging dopamine transporters. J Nucl Med. 1998;39:2069–76.PubMed

167.

Kuikka JT, Baulieu JL, Hiltunen J, Halldin C, Bergström KA, Farde L, et al. Pharmacokinetics and dosimetry of iodine-123 labelled PE2I in humans, a radioligand for dopamine transporter imaging. Eur J Nucl Med. 1998;25:531–4.PubMedCrossRef

168.

Ribeiro MJ, Ricard M, Lièvre MA, Bourgeois S, Emond P, Gervais P, et al. Whole-body distribution and radiation dosimetry of the dopamine transporter radioligand [(11)C]PE2I in healthy volunteers. Nucl Med Biol. 2007;34:465–70.PubMedCrossRef

169.

Murthy R, Harris P, Simpson N, Van Heertum R, Leibel R, Mann JJ, et al. Whole body [11C]-dihydrotetrabenazine imaging of baboons: biodistribution and human radiation dosimetry estimates. Eur J Nucl Med Mol Imaging. 2008;35:790–7.PubMedCrossRef

Title: EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0
Authors: Silvia Morbelli
Giuseppe Esposito
Javier Arbizu
Henryk Barthel
Ronald Boellaard
Nico I. Bohnen
David J Brooks
Jacques Darcourt
John C. Dickson
David Douglas
Alexander Drzezga
Jacob Dubroff
Ozgul Ekmekcioglu
Valentina Garibotto
Peter Herscovitch
Phillip Kuo
Adriaan Lammertsma
Sabina Pappata
Iván Peñuelas
John Seibyl
Franck Semah
Livia Tossici-Bolt
Elsmarieke Van de Giessen
Koen Van Laere
Andrea Varrone
Michele Wanner
George Zubal
Ian Law
Publication date: 01-07-2020
Publisher: Springer Berlin Heidelberg
Keywords: Computed Tomography
Computed Tomography
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 8/2020
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-020-04817-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0

Abstract

Purpose

Methods

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2020

Staging and quantification of florbetaben PET images using machine learning: impact of predicted regional cortical tracer uptake and amyloid stage on clinical outcomes

68Ga-PSMA PET/CT better characterises localised prostate cancer after MRI and transperineal prostate biopsy: Is 68Ga-PSMA PET/CT guided biopsy the future?

Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer

In vivo characterization of [18F]AVT-011 as a radiotracer for PET imaging of multidrug resistance

Reply to: Clinical brain PET research must embrace multi-centre collaboration and data sharing or risk its demise: emphasis should also be placed on the critical role of image analysis schemes

False-negative 18F-PSMA-1007 PET/CT in metastatic prostate cancer related to high physiologic liver uptake